PDL BioPharma Issues Downbeat Q3 Revenue Forecast
PDL BioPharma Inc (NASDAQ: PDLI) projected downbeat third-quarter revenue.
PDL BioPharma now projects Q3 revenue of $83 million, versus analysts' estimates of $88 million.
PDL BioPharma shares gained 0.17% to $5.80 in after-hours trading.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.